1391063-17-4
                            中文名称
                            博舒替尼杂质
                            
                        
                        
                        
                            英文名称
                            Bosutinib Impurity 5
                            
                        
                        
                        
                            CAS
                            
                            1391063-17-4
                            
                        
                        
                        
                            分子式
                            C26H29Cl2N5O3
                            
                        
                        
                        
                            分子量
                            530.45
                            
                        
                        
                        
                            MOL 文件
                            1391063-17-4.mol
                            
                        
                        
                        
                            更新日期
                            
                            2025/10/27 10:13:30
                            
                        
                        
                     1391063-17-4 结构式
                        1391063-17-4 结构式
                    基本信息
中文别名
博舒替尼异构体伯舒替尼杂质5
波舒替尼异构体1
化合物 T28374
英文别名
Bosutinib isomer 1Bosutinib Isomer I
Bosutinib Isomer I (PF-06651481-00)
3-Quinolinecarbonitrile, 4-[(3,5-dichloro-4-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-
所属类别
分析化学:药典标准品和杂质标准品物理化学性质
储存条件room temp
溶解度可溶于氯仿(轻微)、DMSO(轻微)、甲醇(轻微、加热)
形态固体
颜色白色至浅棕色
稳定性Stable under recommended storage conditions., Stable Under Recommended Storage C
应用领域
用途一
Kinase inhibitors, such as?bosutinib,?are useful cancer drugs but their target specificity is not fully understood. 4-[(3,5-Dichloro-4-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile has been employed as a clinical kinase inhibitor bosutinib to elucidate the recognition mechanism between the ATP-binding site and the compound.